Novartis' strong drug pipeline and financials support an 11% annual return by 2027. Learn why NVS stock offers 33% return ...

Investor Summit has drawn US$115 billion in investments, alongside the launch of its Industrial Policy 2025-30.

In this process, royalty recipients often face the issue where multiple small future royalty streams cannot fulfill ongoing large lump-sum R&D funding needs. The mismatch is where Royalty Pharma ...

Wide areas of the pharmaceutical industry are ripe for enhancement, as examples from the industry’s top innovators reflect.

US President Donald Trump kicked off his second term with a series of directives aimed at the US National Institutes of ...

A look at the M&A and stock market pictures for full-year 2024—and the potential strategic implications for pharma and ...

The Pharmaceutical Excipients Market is poised for significant growth between 2025 and 2035, driven by the increasing demand for drug formulations and advancements in the pharmaceutical industry.

As the demand for novel therapies and personalized medicine surges, leaders are uniquely positioned to create a culture of creativity, collaboration and innovation.

In a recent article titled “ Big Pharma says ‘Thanks, but No Thanks’ to their own HEOR groups, ” Professor Scott Ramsey from ...

Leicester met with the President of Uzbekistan, Shavkat Mirziyoyev, for the official launch of one of its international ...

Nandita Vijayasimha, Bengaluru Thursday, February 13, 2025, 08:00 Hrs [IST] ...